Tolero Pharmaceuticals Inc., a medical technology company focused on developing treatments for hematological diseases, has opened its new headquarters in Lehi. Company officials, including CEO and founder David J. Bearss, joined state and local officials and a leadership team from the firm’s
Japanese parent company, Sumitomo Dainippon Pharma Co. Ltd., at a recent ribbon-cutting ceremony.
“On behalf of all our employees, I am pleased to be a corporate citizen of Lehi and proud to call Utah our home,” said Bearss. “Opening a new headquarters and cutting-edge research facility underscores Tolero’s commitment to science that may make a difference in the lives of cancer patients across the country, in the state of Utah, and here in our own backyard.”
Tolero has been headquartered in Lehi since its inception in 2011. The new facility includes a research laboratory where the company will continue to advance its pipeline of potential treatments for acute myeloid leukemia and other cancers.
Tolero is a clinical-stage biopharmaceutical company researching and developing treatments for patients with oncological and hematological diseases. Its pipeline targets biological drivers of blood disorders to treat leukemias, anemia and solid tumors, as well as targets of drug resistance and transcriptional control.